申请人:Medivation Technologies, Inc.
公开号:US20130123277A1
公开(公告)日:2013-05-16
This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[3,4-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in the variety of therapeutic application, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or neuronal disorder.
本公开涉及新的杂环化合物,可用于调节个体中的组胺受体。其中描述了吡啶并[3,4-b]吲哚,以及包含这些化合物的药物组合物和使用这些化合物进行各种治疗应用的方法,包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。